首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients
【2h】

Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients

机译:转录因子激活增强子结合蛋白4(TFAP4)的过表达预测结直肠癌患者的预后不良

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Transcription factor activating enhancer binding protein 4 (TFAP4) is an important regulator in the genesis and progression of human cancers. Overexpression of TFAP4 has been found to be correlated with several malignancies. The present study assessed the clinical importance of TFAP4 in colorectal cancer (CRC). First, immunohistochemistry was used to analyze TFAP4 expression and the association of TFAP4 expression with clinicopathological features on a tissue microarray containing 208 CRC patients. The results revealed that TFAP4 protein expression was significantly upregulated in CRC tissues compared with that in normal colon tissues (P<0.001). Of note, statistical analysis revealed that TFAP4 expression was significantly correlated with a high pathological grade (P=0.034), advanced clinical stage (P=0.024), enhanced tumor invasion (P=0.002) and lymph node metastasis (P=0.041). In addition, the Cancer Genome Atlas dataset further validated that TFAP4 mRNA levels were increased in CRC with advanced clinical stage (P=0.026), lymph node metastasis (P=0.018) and vascular invasion (P=0.046). Kaplan-Meier survival analysis demonstrated that CRC patients with high TFAP4 expression had shorter overall survival compared with those with low TFAP4 expression (P=0.011). Importantly, overexpression of TFAP4 was a valuable independent prognostic factor for CRC patients (hazard ratio, 8.200; 95% confidence interval, 1.838–36.591; P=0.006). In summary, TFAP4 may have an important role in CRC progression and upregulation of TFAP4 may be a predictor of poor prognosis for CRC patients.
机译:转录因子激活增强子结合蛋白4(TFAP4)是人类癌症的发生和发展中的重要调节器。已经发现TFAP4的过表达与几种恶性肿瘤相关。本研究评估了TFAP4在结直肠癌(CRC)中的临床重要性。首先,在包含208例CRC患者的组织芯片上,采用免疫组织化学分析TFAP4的表达以及TFAP4表达与临床病理特征的关系。结果表明,与正常结肠组织相比,CRC组织中的TFAP4蛋白表达显着上调(P <0.001)。值得注意的是,统计分析表明,TFAP4表达与高病理分级(P = 0.034),晚期临床阶段(P = 0.024),增强的肿瘤浸润(P = 0.002)和淋巴结转移(P = 0.041)显着相关。此外,Cancer Genome Atlas数据集进一步验证了CRC的TFAP4 mRNA水平随着临床晚期(P = 0.026),淋巴结转移(P = 0.018)和血管浸润(P = 0.046)而升高。 Kaplan-Meier生存分析表明,TFAP4表达高的CRC患者与TFAP4表达低的CRC患者相比,总生存期短(P = 0.011)。重要的是,对于CRC患者,TFAP4的过表达是有价值的独立预后因素(危险比为8.200; 95%置信区间为1.838–36.591; P = 0.006)。总之,TFAP4可能在CRC进展中起重要作用,而TFAP4的上调可能是CRC患者预后不良的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号